Aldeyra Therapeutics to seek FDA dispute review for reproxalap
The company said it plans to submit a Formal Dispute Resolution Request to the FDA over reproxalap for dry eye disease. Aldeyra also said it now expects operational cash runway into 2029 based on reported cash and cash equivalents of $45.1 million as of June 30, 2026.
Story updates
11:07:48 AM UTC
SquawkNews
Sept 29 (Reuters) — Aldeyra Therapeutics Inc: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease Aldeyra Therapeutics - To Submit Formal Dispute Resolution Request To Fda For Reproxalap Aldeyra Therapeutics - Fdrr Submission And Fda Meeting Expected In Q4 2026 Aldeyra Therapeutics - Fdrr To Appeal March 16, 2026 Complete Response Letter Denying Nda For Reproxalap Source text:... Further company coverage: ALDX.O (Reuters.Briefs@thomsonreuters.com;;)
11:08:12 AM UTC
SquawkNews
Aldeyra updated financial guidance to extend its operational cash runway into 2029. Update reflects reported cash and cash equivalents of $45.1 million as of June 30, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202609290700BIZWIRE_USPR_____20260929_BW404066) on September 29, 2026, and is solely responsible for the information contained therein. (C)